MAIA Biotechnology, Inc. (MAIA) is an innovator in the field of oncology dedicated to transforming the standpoints of broader cancer care. This groundbreaking company aims to provide novel therapeutic options to patients fighting serious or life-threatening diseases, with a predominant focus on cancer. Through its commitment to follow the underlying principle of "Doing Well by Doing Good", MAIA serves its stakeholders while delivering breakthrough solutions for the betterment of health worldwide.
The company leverages advanced sciences combined with superb business models to achieve the highest standards of technological development and commercial operations. MAIA Biotechnology is home to a dynamic team, including leading scientists, highly-skilled medical professionals and industry experts. These individuals work hand in hand with the core mission to significantly alleviate the struggle experienced by cancer patients and their loved ones by harnessing the power of novel science.
The recent advances of MAIA are aligned with its cutting-edge TAIL7 program, their lead product candidate, which offers a unique approach in treating various types of cancers that often evade the current therapeutic offerings. The aim is to disrupt the interplay between the DNA replication machinery and pivotal oncogenic pathways, therefore blocking cancer cells' proliferation.
Moreover, MAIA Biotechnology is a pioneer in developing a novel class of therapeutics known as Senescence-Eliciting Therapies (SETs). SETs exploit the process of cellular aging (senescence) to halt the proliferation of cancer cells. This offers an entirely new avenue towards successful cancer treatment, demonstrating the true Spirit of Innovation that drives MAIA Biotechnology.
The company's efforts extend beyond oncology's traditional scope. They have launched an initiative to discover and develop novel therapies targeting the SARS-CoV-2 virus, clearly showcasing their adaptability and responsiveness towards global health crises.
MAIA Biotechnology, Inc. operates in collaboration with various academic, industry and governmental entities to foster its mission. This company exemplifies the quintessential intersection of dedicated scientific endeavor and responsible business conduct to make a significant impact by improving patient care worldwide.
With strong leadership, a mission-driven team, innovative therapeutic developments, and an adaptive approach, MAIA Biotechnology, Inc., is setting new standard in the field of oncology and beyond. It continues to strive to redefine cancer treatment and aims to leave a lasting positive impact on the world health scenario.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
MAIA Biotechnology has dosed the first U.S. patient in its Phase 2 THIO-101 clinical trial for non-small cell lung cancer, evaluating its lead candidate, ateganosine. This U.S. expansion is supported by a $2.3 million NIH grant, building on previous trial data showing extended overall survival and the drug's FDA Fast Track designation. The company aims to address unmet needs in advanced lung cancer treatment and potentially pursue accelerated FDA approval.
MAIA Biotechnology has dosed its first U.S. patient in the Phase 2 THIO-101 trial for ateganosine, targeting third-line non-small cell lung cancer (NSCLC). This U.S. expansion is supported by a $2.3 million NIH grant and follows FDA clearance of an amended IND. The trial evaluates ateganosine, a telomere-targeting immunotherapy, in combination with a checkpoint inhibitor, building on previous data showing improved overall survival.